Question 1

Is BPC-157 FDA approved?

Accepted Answer

No — and that's not expected to change at the July 23, 2026 PCAC meeting either. Approval requires a full New Drug Application, which BPC-157 hasn't entered. The PCAC discussion is specifically about the compounding pathway (Section 503A) — a narrower question: should licensed compounders be allowed to use BPC-157-related substances when filling patient-specific prescriptions?

Question 2

Can I buy BPC-157 here?

Accepted Answer

No. BPC157.now is editorial coverage, full stop. We don't sell, fulfill, ship, or link to sellers. That's a firm editorial policy, not just a legal disclaimer. Vendors marketing BPC-157 online are operating in a gray area we cover — not one we participate in.

Question 3

What exactly is Section 503A, and why does it matter for BPC-157?

Accepted Answer

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies — it lets licensed pharmacists prepare patient-specific medications using substances from an FDA-approved list called the 503A bulks list. BPC-157 is not currently on that list. The July 2026 PCAC discussion is about whether it should be considered for addition. Even a favorable recommendation would still require formal FDA rulemaking before anything changed.

Question 4

I see BPC-157 sold online everywhere. How is that legal?

Accepted Answer

Much of it probably isn't. Many vendors sell under labels like "for research use only" or "not for human consumption" — those disclaimers are not legal exemptions from FDA oversight, they're marketing hedges. The FDA has limited enforcement resources and has historically prioritized large-scale violations. The legal gray area is real, which is exactly why the formal regulatory process matters.

Question 5

Does this site offer prescriptions, telehealth, or provider access?

Accepted Answer

No. We are not a telehealth platform, a pharmacy, a compounding facility, or a provider-matching service in any operational sense. Our "Provider Match" feature is a forward-facing notification list: if compliant access options emerge after formal regulatory changes, we'll alert subscribers. That alert is not a referral, a prescription, or an order.

Question 6

What is the Provider Match waitlist?

Accepted Answer

It's an early-signal subscription. If formal FDA action opens a compliant compounding pathway for BPC-157, we'll send an educational alert explaining what changed and what it does and doesn't mean. Signing up is not a purchase, a prescription, or a reservation. It's a heads-up.

Question 7

What does a 'negative' PCAC recommendation actually mean?

Accepted Answer

If the committee recommends against including BPC-157 on the 503A bulks list, it reinforces the current restricted status and makes a compliant compounding pathway significantly less likely near-term. It doesn't make BPC-157 "more illegal" than it is now — it removes a potential regulatory on-ramp. The FDA isn't required to follow advisory recommendations, but it usually does.

Question 8

What happens if the PCAC recommends inclusion on July 23, 2026?

Accepted Answer

A favorable PCAC recommendation is not instant access. The FDA would still need to complete formal rulemaking to add BPC-157 to the 503A bulks list — a process that typically takes months to over a year. A positive recommendation would be meaningfully important news for the prospect of compliant compounded access. But it would be a beginning, not an endpoint.

Question 9

Is BPC157.now affiliated with any vendor, clinic, or pharmacy?

Accepted Answer

No. We have no financial relationships with any vendor, compounding pharmacy, telehealth clinic, or anyone who sells, distributes, or promotes BPC-157 or related products. Our editorial coverage is fully independent.

Question 10

Where do I find the FDA briefing documents when they're released?

Accepted Answer

The FDA posts PCAC briefing materials on FDA.gov in the weeks before the advisory meeting. They typically include the FDA's own review of physicochemical characterization, safety data, effectiveness evidence, and historical use. We'll publish a plain-English summary the day they become available. Subscribers get emailed when we publish.

Question 11

What happens if regulations change?

Accepted Answer

Any material change would follow formal FDA action. The sequence is: PCAC recommendation → FDA notice of proposed rulemaking → public comment period → final rule. Each step takes time, and we cover every one. Subscribers get updates within hours of publication — not days later when the news has been distorted by a dozen other outlets.

Question 12

Is this medical advice?

Accepted Answer

No. Nothing on BPC157.now is medical advice. If BPC-157 is relevant to your health situation, you need to talk to a licensed healthcare professional who can factor in your specific circumstances and the current legal status — which can change.

Question 13

How do I contact BPC157.now?

Accepted Answer

Visit the Contact page — our email address is displayed there in a format that prevents scraping. We read everything that comes in.

Question 14

Where can I learn about PDA+ Pentadeca Arginate?

Accepted Answer

We've published a comparison article covering the key differences between BPC-157 and PDA+ Pentadeca Arginate, including their separate regulatory profiles. They're distinct compounds — information about one doesn't transfer to the other. For dedicated coverage, pentadecaarginate.com is an independent educational resource focused specifically on PDA+.

Question 15

How long does the full 503A rulemaking process take after a PCAC recommendation?

Accepted Answer

The full rulemaking process — from a favorable PCAC recommendation to a final rule — typically takes many months to over a year. After the recommendation, the FDA must publish a notice of proposed rulemaking (NPRM), accept a public comment period (typically 60–90 days), review all comments, and then issue a final rule. There is no statutory deadline for completing this process.

Question 16

What are FDA briefing documents and when will they be released?

Accepted Answer

FDA briefing documents are detailed technical files published before PCAC meetings, usually in the weeks leading up to the hearing. They contain the FDA's own review of the substance's physicochemical characterization, safety data, clinical evidence, and the agency's preliminary assessment. When BPC-157 briefing documents are released, BPC157.now will publish plain-language summaries within 24 hours.

Question 17

Is BPC-157 legal to possess in the United States?

Accepted Answer

This is a legal question, not an editorial one, and the answer depends on specific circumstances that change with regulatory developments. We are not lawyers and cannot provide legal advice. For questions about the current legal status of BPC-157 for your specific situation, consult a regulatory attorney.

Question 18

What is the difference between 503A and 503B compounding?

Accepted Answer

Section 503A covers traditional compounding pharmacies — they prepare medications for individual patients on a prescription basis and can only use substances from an approved list. Section 503B covers 'outsourcing facilities' — larger-scale compounders registered with the FDA that can produce medications in bulk without individual prescriptions. BPC-157 is not permitted under either pathway currently.

Question 19

How do I know if a BPC-157 product sold online is legitimate?

Accepted Answer

This is not a question we can answer with confidence for any specific product — and that's precisely the point. Without FDA oversight and the regulatory framework that comes with it, consumers have no reliable way to verify the identity, purity, potency, or manufacturing quality of unregulated products. This is why the regulatory process matters.

Frequently asked